Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP

Pharvaris N.v. PHVS

8 fiscal years on record · EUR · FY2025 reported · SEC filings only
€-175.7M
€-137.2M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

·
Revenue, FY2025 · full 8-year series below
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
ROE
FY2025 · ROE -65.2%
-50%
201820212025
Three returns, three denominators.
Return on capital employedNot available: we don't have total assets or current liabilities for this period.

Each EUR of equity lost 65 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow €M
FY2025 · FCF -137.2
-50M-100M
201820212025

Total assetsEUR 301.5M
CashEUR 291.7M

Not available: we don't have the total debt figure for this period.

The 8-year record

8 fiscal years
Every figure from documents filed with the SEC · EUR

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
PHVS, 8-year financial record
Metric 20252024202320222021202020192018
Revenue €B◌◌◌◌◌◌◌◌
Operating income €B−0.2−0.1−0.1−0.1−0.0−0.0−0.0−0.0
EBITDA €B◌◌◌◌◌◌◌◌
Income tax €B0.00.00.00.00.0−0.00.00.0
Net income €B−0.2−0.1−0.1−0.1−0.0−0.0−0.0◌
Free cash flow €B−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0
EPS, diluted €−2.97−2.48−2.63−2.27−1.40◌◌◌
Dividend / sh €◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend————————
ROE %−65.2−41.2−37.8−43.1−28.4−45.4−68.0−87.1

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 2 failures in 20 reconciliationsAUDITED

Reconciled in 6 of the 8 fiscal years we could check. 14 checks were skipped: EPS is not tagged before 2021. 12 checks were skipped: the balance sheet is not tagged before 2019.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency2 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code P7
Fiscal year endsDecember 31
Data on record since2018

Share this section

Download image